| Assessment Status | Rapid Review Complete |
| HTA ID | 24044 |
| Drug | Amivantamab |
| Brand | Rybrevant® |
| Indication | Amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI) |
| Assessment Process | |
| Rapid review commissioned | 25/10/2024 |
| Rapid review completed | 13/12/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab compared with the current standard of care. |
